Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

被引：0
|
作者：
Kawachi, H. [1 ]
Tamiya, M. [1 ]
Tamiya, A. [2 ]
Ishii, S. [2 ]
Hirano, K. [3 ]
Matsumoto, H. [3 ]
Yokoyama, T. [4 ]
Ishida, T. [4 ]
Ryota, K. [5 ]
Fujimoto, D. [6 ]
Hosoya, K. [6 ]
Suzuki, H. [7 ]
Hirashima, T. [8 ]
Kanazu, M. [9 ]
Sawa, N. [10 ]
Uchida, J. [11 ]
Morita, M. [12 ]
Makio, T. [13 ]
Hara, S. [13 ]
Kumagai, T. [1 ]
机构：
[1] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan
[2] Kinki Chuo Chest Med Ctr, Internal Med, Sakai, Osaka, Japan
[3] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, Amagasaki, Hyogo, Japan
[4] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[5] Himeji Med Ctr, Resp Med, Himeji, Hyogo, Japan
[6] Kobe City Med Ctr Gen Hosp, Resp Med, Kobe, Hyogo, Japan
[7] Osaka Habikino Med Ctr, Thorac Oncol, Habikino, Japan
[8] Osaka Prefectural Habikino Hosp, Thorac Oncol, Habikino, Japan
[9] Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[10] Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan
[11] Osaka Gen Med Ctr, Resp Med, Osaka, Japan
[12] Kobe City Med Ctr West Hosp, Resp Med, Kobe, Hyogo, Japan
[13] Itami City Hosp, Resp Med, Itami, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1514P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
    Velcheti, Vamsidhar
    Chandwani, Sheenu
    Chen, Xin
    Pietanza, M. Catherine
    Burke, Thomas
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Three-Year Outcomes with First-Line Pembrolizumab, in Patients with Non-Small-Cell Lung Cancer and A PD-L1 Tumor Proportion Score >90%
    Ricciuti, B.
    Elkrief, A. Arielle
    Lin, J.
    Altan, M.
    Alessi, J.
    Gandhi, M.
    Pecci, F.
    Lamberti, G.
    Di Federico, A.
    Wang, X.
    Pabon, C.
    Zhang, J.
    Lindsey, J.
    Sharma, B.
    Felt, K.
    Nishino, M.
    Sholl, L.
    Rodig, S.
    Gainor, J.
    Heymach, J.
    Schoenfeld, A.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S77 - S77
  • [23] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [24] Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
    Ricciuti, Biagio
    Elkrief, Arielle
    Machado Alessi, Joao Victor
    Wang, Xinan
    de Castro Barrichello, Adriana Paula
    Pecci, Federica
    Lamberti, Giuseppe
    Lindsay, James
    Sharma, Bijaya
    Felt, Kristen
    Nishino, Mizuki
    Sholl, Lynette M.
    Rodig, Scott J.
    Schoenfeld, Adam Jacob
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
    Fujii, Hironori
    Araki, Ayumu
    Iihara, Hirotoshi
    Kaito, Daizo
    Hirose, Chiemi
    Kinomura, Motohiko
    Yamazaki, Mizuki
    Endo, Junki
    Inui, Toshiya
    Yanase, Komei
    Sasaki, Yuka
    Gomyo, Takenobu
    Sakai, Chizuru
    Kawae, Daisuke
    Kitamura, Yu
    Fukui, Masachika
    Kobayashi, Ryo
    Ohno, Yasushi
    Suzuki, Akio
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (04)
  • [26] Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    Cobb, P. W.
    Hochmair, M.
    Schuler, M. H. H.
    Riely, G. J.
    Rojas, C. I.
    Kim, S. J.
    Chen, X.
    Lara-Guerra, H.
    Felip, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S871 - S872
  • [27] Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer
    Imai, Hisao
    Kishikawa, Takayuki
    Minemura, Hiroyuki
    Yamada, Yutaka
    Ibe, Tatsuya
    Yamaguchi, Ou
    Mouri, Atsuto
    Hamamoto, Yoichiro
    Kanazawa, Kenya
    Kasai, Takashi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    Minato, Koichi
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    CANCER MEDICINE, 2021, 10 (20): : 6971 - 6984
  • [28] Advanced non-small cell lung cancer with PD-L1≥50%: Pembrolizumab alone or combined with chemotherapy
    Han, B.
    Han, B.
    Zhang, B.
    Hu, M.
    Wang, Y.
    Yang, Z.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S759
  • [29] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
    Dudnik, Elizabeth
    Moskovitz, Mor
    Rottenberg, Yakir
    Lobachov, Anastasiya
    Mandelboim, Rinat
    Shochat, Tzippy
    Urban, Damien
    Wollner, Mira
    Nechushtan, Hovav
    Rotem, Ofer
    Zer, Alona
    Daher, Sameh
    Bar, Jair
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [30] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
    Theelen, Willemijn S. M. E.
    Baas, Paul
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
12345